Celator Pharma (CPXX) 2.05 $CPXX
Celator Pharmaceuticals Inc.'s CEO Scott Jackson and President Lawrence Mayer Interviewed by The Life Sciences Report
Marketwired - Wed Apr 22, 8:01AM CDT
Celator Pharmaceuticals Inc.'s (NASDAQ: CPXX) remarkable drug combination strategy has produced a cancer-fighting duo endowed with a coveted fast-track designation. Scott Jackson, the company's CEO, and Lawrence Mayer, president, chief scientific officer and founder, tell The Life Sciences Report about what sets Celator apart, and reveal profit-generating milestones that investors should keep on their scopes.
CPXX: 2.05 (+0.10)
Celator® Pharmaceuticals Presents Data at the American Association for Cancer Research Annual Meeting
PR Newswire - Wed Apr 22, 7:00AM CDT
Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced the presentation of data for CPX-351, its lead product candidate, at the American Association for Cancer Research (AACR) Annual Meeting in Philadelphia, PA on April 18-22, 2015.
CPXX: 2.05 (+0.10)
Celator® Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting
PR Newswire - Mon Apr 06, 7:00AM CDT
Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that data for CPX-351, its lead product candidate, will be presented at the American Association for Cancer Research (AACR) Annual Meeting in Philadelphia, PA on April 18-22, 2015.
CPXX: 2.05 (+0.10)
Celator® Pharmaceuticals to Present at 14th Annual Needham Healthcare Conference
PR Newswire - Wed Apr 01, 7:00AM CDT
Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that Scott Jackson, Chief Executive Officer, will present an overview of the company at the 14th Annual Needham Healthcare Conference on Tuesday, April 14, 2015 at 11:20 a.m. ET in New York, N.Y.
CPXX: 2.05 (+0.10)
Celator reports 4Q loss
Automated Insights - Tue Mar 17, 3:40PM CDT
PRINCETON, N.J. (AP) _ Celator Pharmaceuticals Inc. (CPXX) on Tuesday reported a loss of $2.4 million in its fourth quarter.
CPXX: 2.05 (+0.10)
Celator Pharmaceuticals EPS of -$0.07
Seeking Alpha - at Seeking Alpha - Tue Mar 17, 3:20PM CDT
CPXX: 2.05 (+0.10)
Celator® Pharmaceuticals Announces Business Update and Fourth Quarter and Full Year 2014 Financial Results
PR Newswire - Tue Mar 17, 3:01PM CDT
Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2014.
CPXX: 2.05 (+0.10)
Celator® Pharmaceuticals Announces Lawrence Mayer, Ph.D., Founder, President and Chief Scientific Officer Was Inducted to the American Institute for Medical and Biological Engineering
PR Newswire - Tue Mar 17, 7:00AM CDT
Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced the induction of Lawrence Mayer, Ph.D., founder, president and chief scientific officer of Celator, to the American Institute for Medical and Biological Engineering (AIMBE) College of Fellows.
CPXX: 2.05 (+0.10)
Celator® Pharmaceuticals to Present at Future Leaders in the Biotech Industry Conference
PR Newswire - Thu Mar 12, 7:00AM CDT
Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that Scott Jackson, Chief Executive Officer, will present an overview of the company at the Future Leaders in the Biotech Industry Conference on Friday, March 20, 2015 at 4:00 p.m. ET in New York City.
CPXX: 2.05 (+0.10)
Celator® Pharmaceuticals to Report Fourth Quarter and Year-End 2014 Financial Results on March 17, 2015
PR Newswire - Wed Mar 11, 7:30AM CDT
Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that it will host a conference call and live audio webcast on Tuesday, March 17, 2015 at 4:30 p.m. ET to report fourth quarter and year-end 2014 financial results.
CPXX: 2.05 (+0.10)
Celator Pharmaceuticals names Jean-Pierre Bizzari to board
M2 - Tue Mar 03, 4:59AM CST
Biopharmaceutical company Celator Pharmaceuticals (NasdaqCM:CPXX) revealed on Monday the addition of Jean-Pierre Bizzari, MD to its board of directors.
CPXX: 2.05 (+0.10)
Celator® Pharmaceuticals Appoints Jean-Pierre Bizzari to Board of Directors
PR Newswire - Mon Mar 02, 6:00AM CST
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced the appointment of Jean-Pierre Bizzari, M.D. to its Board of Directors.
CPXX: 2.05 (+0.10)
Celator® Pharmaceuticals to Present at BIO CEO and Investor Conference
PR Newswire - Mon Feb 02, 6:00AM CST
Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that Scott Jackson, Chief Executive Officer, will present an overview of the company at the BIO CEO and Investor Conference on Tuesday, February 10, 2015 at 11:30 a.m. ET in New York City.
CPXX: 2.05 (+0.10)
Convert Catalysts Into Profits: Sagient Research's Edward Stopke
Life Sciences Report - Seeking Alpha - Fri Jan 23, 7:51AM CST
The biotech sector is teeming with companies racing to bring the hot new drug or therapy to the marketplace. But realistically assessing the therapeutic potential of pipeline products is the healthy approach for selecting a winner. In this interview...
CPXX: 2.05 (+0.10), RPTP: 10.56 (-0.17), SRPT: 13.52 (+0.04), CLDX: 28.95 (+1.08), PTCT: 70.98 (unch), RMTI: 10.82 (+0.13), ATHX: 1.34 (+0.01), CUR: 1.96 (-0.04)
Celator blood cancer drug candidate Fast Track'd
Seeking Alpha - at Seeking Alpha - Tue Jan 20, 10:54AM CST
CPXX: 2.05 (+0.10)
Celator® Pharmaceuticals Receives FDA Fast Track Designation For CPX-351 For The Treatment Of Elderly Patients With Secondary Acute Myeloid Leukemia
PR Newswire - Tue Jan 20, 6:00AM CST
Celator Pharmaceuticals, Inc. (NASDAQ: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for CPX-351 (cytarabine:daunorubicin) for the treatment of elderly patients with secondary Acute Myeloid Leukemia (AML).
CPXX: 2.05 (+0.10)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jan 12, 11:46AM CST
CLUB: 6.36 (-0.02), FRO: 2.77 (-0.20), NES: 3.52 (-0.15), ARWR: 6.88 (+0.14), BBW: 20.09 (+0.15), TKMR: 18.38 (-0.14), NADL: 1.51 (+0.01), TIF: 85.10 (+0.95), BITA: 57.15 (+0.89), CPXX: 2.05 (+0.10), AGEN: 6.08 (+0.21), TOPS: 1.07 (-0.03), IRMD: 15.70 (+0.03), FMI: 48.71 (-0.96), SRPT: 13.52 (+0.04), REXX: 4.77 (-0.04), LOCM: 0.66 (-0.02), BLFS: 2.01 (-0.01), SNDK: 68.48 (+0.56), AWX: 3.65 (-0.02)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jan 12, 8:14AM CST
EYES: 13.26 (-0.06), ZIOP: 10.88 (+0.03), OIBR: 2.07 (-0.04), ARWR: 6.88 (+0.14), TKMR: 18.38 (-0.14), SN: 14.18 (-0.30), TIF: 85.10 (+0.95), NBG: 1.19 (+0.12), BMY: 66.60 (-0.21), LULU: 65.67 (-0.68), CPXX: 2.05 (+0.10), AGEN: 6.08 (+0.21), GDP: 3.58 (-0.10), FMI: 48.71 (-0.96), ASNA: 15.03 (-0.07), NPSP: 45.97 (+0.01), AMCO: 1.06 (-0.02), SNDK: 68.48 (+0.56)
Celator Pharma up on Phase 2 results
Seeking Alpha - at Seeking Alpha - Mon Jan 12, 8:11AM CST
CPXX: 2.05 (+0.10)
Celator® Pharmaceuticals Announces Publication Of Promising Phase 2 Data For CPX-351 In First Relapse Acute Myeloid Leukemia Patients
PR Newswire - Mon Jan 12, 6:00AM CST
Celator Pharmaceuticals, Inc. (NASDAQ: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced the publication of Phase 2 data evaluating CPX-351 in adult patients with first-relapse acute myeloid leukemia (AML) in Cancer, a peer-reviewed journal of the American Cancer Society. The study manuscript entitled, "Phase 2, Multicenter, Randomized Trial of CPX-351 (cytarabine:daunorubicin) Liposome Injection Versus Intensive Salvage Therapy in Adults With First Relapse AML," appears in the January 15, 2015 issue.
CPXX: 2.05 (+0.10)
Celator Pharmaceuticals Inc.'s CEO Scott Jackson and President Lawrence Mayer Interviewed by The Life Sciences Report
Marketwired - Wed Apr 22, 8:01AM CDT
Celator Pharmaceuticals Inc.'s (NASDAQ: CPXX) remarkable drug combination strategy has produced a cancer-fighting duo endowed with a coveted fast-track designation. Scott Jackson, the company's CEO, and Lawrence Mayer, president, chief scientific officer and founder, tell The Life Sciences Report about what sets Celator apart, and reveal profit-generating milestones that investors should keep on their scopes.
CPXX: 2.05 (+0.10)
Celator® Pharmaceuticals Presents Data at the American Association for Cancer Research Annual Meeting
PR Newswire - Wed Apr 22, 7:00AM CDT
Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced the presentation of data for CPX-351, its lead product candidate, at the American Association for Cancer Research (AACR) Annual Meeting in Philadelphia, PA on April 18-22, 2015.
CPXX: 2.05 (+0.10)
Celator® Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting
PR Newswire - Mon Apr 06, 7:00AM CDT
Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that data for CPX-351, its lead product candidate, will be presented at the American Association for Cancer Research (AACR) Annual Meeting in Philadelphia, PA on April 18-22, 2015.
CPXX: 2.05 (+0.10)
Celator® Pharmaceuticals to Present at 14th Annual Needham Healthcare Conference
PR Newswire - Wed Apr 01, 7:00AM CDT
Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that Scott Jackson, Chief Executive Officer, will present an overview of the company at the 14th Annual Needham Healthcare Conference on Tuesday, April 14, 2015 at 11:20 a.m. ET in New York, N.Y.
CPXX: 2.05 (+0.10)
Celator reports 4Q loss
Automated Insights - Tue Mar 17, 3:40PM CDT
PRINCETON, N.J. (AP) _ Celator Pharmaceuticals Inc. (CPXX) on Tuesday reported a loss of $2.4 million in its fourth quarter.
CPXX: 2.05 (+0.10)
Celator Pharmaceuticals EPS of -$0.07
Seeking Alpha - at Seeking Alpha - Tue Mar 17, 3:20PM CDT
CPXX: 2.05 (+0.10)
Celator® Pharmaceuticals Announces Business Update and Fourth Quarter and Full Year 2014 Financial Results
PR Newswire - Tue Mar 17, 3:01PM CDT
Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2014.
CPXX: 2.05 (+0.10)
Celator® Pharmaceuticals Announces Lawrence Mayer, Ph.D., Founder, President and Chief Scientific Officer Was Inducted to the American Institute for Medical and Biological Engineering
PR Newswire - Tue Mar 17, 7:00AM CDT
Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced the induction of Lawrence Mayer, Ph.D., founder, president and chief scientific officer of Celator, to the American Institute for Medical and Biological Engineering (AIMBE) College of Fellows.
CPXX: 2.05 (+0.10)
Celator® Pharmaceuticals to Present at Future Leaders in the Biotech Industry Conference
PR Newswire - Thu Mar 12, 7:00AM CDT
Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that Scott Jackson, Chief Executive Officer, will present an overview of the company at the Future Leaders in the Biotech Industry Conference on Friday, March 20, 2015 at 4:00 p.m. ET in New York City.
CPXX: 2.05 (+0.10)
Celator® Pharmaceuticals to Report Fourth Quarter and Year-End 2014 Financial Results on March 17, 2015
PR Newswire - Wed Mar 11, 7:30AM CDT
Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that it will host a conference call and live audio webcast on Tuesday, March 17, 2015 at 4:30 p.m. ET to report fourth quarter and year-end 2014 financial results.
CPXX: 2.05 (+0.10)
Celator Pharmaceuticals names Jean-Pierre Bizzari to board
M2 - Tue Mar 03, 4:59AM CST
Biopharmaceutical company Celator Pharmaceuticals (NasdaqCM:CPXX) revealed on Monday the addition of Jean-Pierre Bizzari, MD to its board of directors.
CPXX: 2.05 (+0.10)
Celator® Pharmaceuticals Appoints Jean-Pierre Bizzari to Board of Directors
PR Newswire - Mon Mar 02, 6:00AM CST
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced the appointment of Jean-Pierre Bizzari, M.D. to its Board of Directors.
CPXX: 2.05 (+0.10)
Celator® Pharmaceuticals to Present at BIO CEO and Investor Conference
PR Newswire - Mon Feb 02, 6:00AM CST
Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that Scott Jackson, Chief Executive Officer, will present an overview of the company at the BIO CEO and Investor Conference on Tuesday, February 10, 2015 at 11:30 a.m. ET in New York City.
CPXX: 2.05 (+0.10)
Convert Catalysts Into Profits: Sagient Research's Edward Stopke
Life Sciences Report - Seeking Alpha - Fri Jan 23, 7:51AM CST
The biotech sector is teeming with companies racing to bring the hot new drug or therapy to the marketplace. But realistically assessing the therapeutic potential of pipeline products is the healthy approach for selecting a winner. In this interview...
CPXX: 2.05 (+0.10), RPTP: 10.56 (-0.17), SRPT: 13.52 (+0.04), CLDX: 28.95 (+1.08), PTCT: 70.98 (unch), RMTI: 10.82 (+0.13), ATHX: 1.34 (+0.01), CUR: 1.96 (-0.04)
Celator blood cancer drug candidate Fast Track'd
Seeking Alpha - at Seeking Alpha - Tue Jan 20, 10:54AM CST
CPXX: 2.05 (+0.10)
Celator® Pharmaceuticals Receives FDA Fast Track Designation For CPX-351 For The Treatment Of Elderly Patients With Secondary Acute Myeloid Leukemia
PR Newswire - Tue Jan 20, 6:00AM CST
Celator Pharmaceuticals, Inc. (NASDAQ: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for CPX-351 (cytarabine:daunorubicin) for the treatment of elderly patients with secondary Acute Myeloid Leukemia (AML).
CPXX: 2.05 (+0.10)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jan 12, 11:46AM CST
CLUB: 6.36 (-0.02), FRO: 2.77 (-0.20), NES: 3.52 (-0.15), ARWR: 6.88 (+0.14), BBW: 20.09 (+0.15), TKMR: 18.38 (-0.14), NADL: 1.51 (+0.01), TIF: 85.10 (+0.95), BITA: 57.15 (+0.89), CPXX: 2.05 (+0.10), AGEN: 6.08 (+0.21), TOPS: 1.07 (-0.03), IRMD: 15.70 (+0.03), FMI: 48.71 (-0.96), SRPT: 13.52 (+0.04), REXX: 4.77 (-0.04), LOCM: 0.66 (-0.02), BLFS: 2.01 (-0.01), SNDK: 68.48 (+0.56), AWX: 3.65 (-0.02)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jan 12, 8:14AM CST
EYES: 13.26 (-0.06), ZIOP: 10.88 (+0.03), OIBR: 2.07 (-0.04), ARWR: 6.88 (+0.14), TKMR: 18.38 (-0.14), SN: 14.18 (-0.30), TIF: 85.10 (+0.95), NBG: 1.19 (+0.12), BMY: 66.60 (-0.21), LULU: 65.67 (-0.68), CPXX: 2.05 (+0.10), AGEN: 6.08 (+0.21), GDP: 3.58 (-0.10), FMI: 48.71 (-0.96), ASNA: 15.03 (-0.07), NPSP: 45.97 (+0.01), AMCO: 1.06 (-0.02), SNDK: 68.48 (+0.56)
Celator Pharma up on Phase 2 results
Seeking Alpha - at Seeking Alpha - Mon Jan 12, 8:11AM CST
CPXX: 2.05 (+0.10)
Celator® Pharmaceuticals Announces Publication Of Promising Phase 2 Data For CPX-351 In First Relapse Acute Myeloid Leukemia Patients
PR Newswire - Mon Jan 12, 6:00AM CST
Celator Pharmaceuticals, Inc. (NASDAQ: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced the publication of Phase 2 data evaluating CPX-351 in adult patients with first-relapse acute myeloid leukemia (AML) in Cancer, a peer-reviewed journal of the American Cancer Society. The study manuscript entitled, "Phase 2, Multicenter, Randomized Trial of CPX-351 (cytarabine:daunorubicin) Liposome Injection Versus Intensive Salvage Therapy in Adults With First Relapse AML," appears in the January 15, 2015 issue.
CPXX: 2.05 (+0.10)
